Nymox Pharmaceutical Corp is a biotechnology business based in the US. Nymox Pharmaceutical shares (NYMX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.41 |
|---|---|
| 52-week range | $0.35 - $2.27 |
| 50-day moving average | $0.81 |
| 200-day moving average | $1.39 |
| Wall St. target price | $10.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.18 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.41 from 2022-07-01
| 1 week (2022-06-24) | -8.89% |
|---|---|
| 1 month (2022-06-02) | 5.13% |
| 3 months (2022-04-01) | -66.39% |
| 6 months (2021-12-31) | -68.46% |
| 1 year (2021-07-02) | -73.89% |
|---|---|
| 2 years (2020-07-02) | -88.80% |
| 3 years (2019-07-02) | 1.51 |
| 5 years (2017-06-30) | 4.4 |
| Gross profit TTM | $1,000 |
|---|---|
| Return on assets TTM | -703.17% |
| Return on equity TTM | -1529.83% |
| Profit margin | 0% |
| Book value | $0.02 |
| Market capitalisation | $37 million |
TTM: trailing 12 months
We're not expecting Nymox Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, Nymox Pharmaceutical's shares have ranged in value from as little as $0.35 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nymox Pharmaceutical's is 1.1402. This would suggest that Nymox Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.